Loxo Oncology News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.02.19	Eli Lilly, Loxo Oncology Report Expiration Of HSR Act Waiting Period (RTTNews)
08.01.19	So Long, Loxo (RTTNews)
08.01.19	AXSM Awes Investors, LOXO Snapped Up For $8 Bln, SAGE Excited, TLC On Watch (RTTNews)
07.01.19	Loxo Oncology Holding On To Substantial Gain In Afternoon Trading (RTTNews)
07.01.19	Lilly To Buy Loxo Oncology In $8.0 Bln Deal (RTTNews)
27.11.18	FDA Okays Loxo Oncology - Bayer Cancer Drug (RTTNews)
29.10.18	Biotech Stocks Facing FDA Decision In November (RTTNews)
21.10.18	Loxo Oncology Announces Larotrectinib Update In Patients With TRK Fusion Cancers (RTTNews)
22.09.18	Week Ahead In Pharmaceuticals: 10 Stocks To Watch (CKPT, SNDX, ADMP...) (RTTNews)
29.05.18	FDA Accepts Larotrectinib New Drug Application and Grants Priority Review (PR Newswire)
27.05.18	An Ear To The Pharma: 12 Stocks To Watch (AIMT, TXMD, MDGL…) (RTTNews)
18.05.18	EIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSI's Cash Strengthens (RTTNews)
04.05.18	Long-Term Power Solutions (PSIX) Investors: Johnson Fistel Investigates Power Solutions International, Inc.; Encourages Long-Term Investors to Contact the Firm (PR Newswire)
10.04.18	Illumina, Loxo Oncology Announce Collaboration - Quick Facts (RTTNews)
26.03.18	Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer (PR Newswire)
21.02.18	Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine (PR Newswire)
20.12.17	Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers (PR Newswire)
04.12.17	Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers (PR Newswire)
14.11.17	Bayer Enters Global Collaboration With Loxo For Larotrectinib, LOXO-195 (RTTNews)
14.11.17	Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer (PR Newswire)
10.10.17	BGNE Hits Record High, SYRS Awaits Catalysts, ALT To Report Data In Q4 (RTTNews)
15.09.17	HALO Just Got Brighter - What Other Pharma Stocks Made News This Week? (RTTNews)
14.09.17	TTOO Catches Investors' Eyes, SIEN Shaping Up, AGTC Slips Into Red (RTTNews)
05.09.17	Stocks Under Scanner in the Biotech Space -- GlycoMimetics, Genocea Biosciences, Inotek Pharma, and Loxo Oncology (PR Newswire)
15.06.17	ALDX Down But Not Out, BTX On Track, MNK Exploring New Use For Acthar (RTTNews)
06.06.17	Gainers & Losers Of June 5: LOXO, CLSN, RDUS, GLYC, JUNO... (RTTNews)
05.06.17	Loxo Oncology Pulls Back Off Best Levels But Remains Sharply Higher (RTTNews)
12.05.17	Loxo Oncology: FDA Grants Orphan Drug Designation To Larotrectinib (RTTNews)
03.04.17	Setback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady Rise (RTTNews)
20.12.16	CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch (RTTNews)
18.12.16	Loxo Oncology Updates Results From Adult Phase 1 Trial Of Larotrectinib (RTTNews)
18.04.16	FDA Snubs CHMA, NICE Is Nice With PTCT, RXII To Effect Reverse Split (RTTNews)
08.11.15	Loxo Oncology TRK Inhibitor LOXO-101 Shows Promising Clinical Activity (RTTNews)
22.04.15	MSTX Study Crosses Halfway Mark, VASC Blooms, ALL Is Well With PFE (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Holcim	91.22	1.56 %	K V
Sonova Hldg	319.70	1.56 %	K V
Lonza Grp	591.00	1.34 %	K V
Sika	231.50	1.27 %	K V
CieFinRichemont	171.70	0.94 %	K V
Swiss Re	138.05	-0.40 %	K V
Zurich Insur Gr	537.20	-0.52 %	K V
Kuehne+Nagel Int	204.60	-0.97 %	K V
Part Grp Hldg	1’389.50	-1.03 %	K V
Givaudan	3’818.00	-3.12 %	K V

Nachrichten zu Loxo Oncology Inc

Aktien Top/Flop

Meistgelesene Nachrichten